Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Return on Sales data on record, last reported at 895.75% in Q4 2025.

  • For Q4 2025, Return on Sales rose 20093.0% year-over-year to 895.75%; the TTM value through Dec 2025 reached 4.81%, up 88645.0%, while the annual FY2025 figure was 4.81%, 88802.0% up from the prior year.
  • Return on Sales reached 895.75% in Q4 2025 per VRDN's latest filing, down from 0.5% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.5% in Q3 2025 and bottomed at 1343.13% in Q2 2025.
  • Average Return on Sales over 5 years is 549.32%, with a median of 668.07% recorded in 2023.
  • Peak YoY movement for Return on Sales: crashed -64956bps in 2023, then skyrocketed 89095bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 135.26% in 2021, then tumbled by -222bps to 436.05% in 2022, then tumbled by -112bps to 925.93% in 2023, then dropped by -18bps to 1096.68% in 2024, then rose by 18bps to 895.75% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 895.75% in Q4 2025, 0.5% in Q3 2025, and 1343.13% in Q2 2025.